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Serum immune complex containing
thrombospondin-1: a novel
biomarker for early rheumatoid
arthritis
The diagnosis of rheumatoid arthritis (RA) is based on classifi-
cation criteria set by the 2010 RA classification criteria includ-
ing serological assessment of rheumatoid factor (RF) and
anticitrulline-containing protein/peptide (anti-CCP) antibody.1 2
Anti-CCP antibody is specific (94–99%) for RA; however, 25%
of patients with established RA and 40% of patients with early
RA are negative for this marker.3 4 Novel biomarkers, especially
for early RA and/or for RA lacking RF and anti-CCP antibody
markers (ie, seronegative RA) are therefore urgently required.
Circulating immune complexes (CICs) present in the human
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body are likely to contain many different antigens that may
reflect underlying disease, so antigens incorporated into CICs
are promising candidates for diagnostic biomarkers. We devel-
oped a novel proteomic strategy (immune complexome ana-
lysis) to identify and profile antigens in CICs and used this
method to analyse CICs in patients with established RA and
controls (healthy donors and patients with osteoarthritis).5
CIC-associated thrombospondin-1 (TSP-1) was found in 81%
and CIC-associated platelet factor 4 (PF4) in 52% of patients
with established RA, but neither protein was found in CICs
from any of the controls.5 Both proteins are known as endogen-
ous inhibitors of angiogenesis6–8; the formation of CICs may
promote angiogenesis. We evaluated the diagnostic potential of
CIC-associated TSP-1 and CIC-associated PF4 in patients with
early RA divided into seropositive and seronegative groups.
Serum samples were collected from 25 disease-modifying
antirheumatic drug (DMARD)-naïve seropositive patients with
early RA (mean±SD age 52.8±18.4 years; 21 women; disease
duration 0.25–12 months; CRP 0.01–8.55 mg/dl) and 15 sero-
negative patients with early RA (mean±SD age 60.5±17.9
years; 8 women; disease duration 1–6 months; CRP 0.02–14.4
mg/dl) at Nagasaki University Hospital. All the seropositive
patients were positive for RF and 20 were positive for anti-CCP
antibody, while all the seronegative patients were negative for
both RF and anti-CCP antibody. The diagnosis of RAwas made
by the 2010 RA classification criteria as well as administration
of DMARDs within the first 12 months.1 2 Serum samples
from 16 patients with Sjögren’s syndrome (SS) (mean±SD age
60.9±13.0 years) and 14 patients with systemic lupus erythe-
matosus (SLE) (mean±SD age 42.6±12.4 years) who fulfilled
the international criteria for the diagnosis of SS9 and SLE10 and
11 healthy donors (mean±SD age 49.5±10.3 years) were used
as controls. CICs purified by magnetic beads with immobilised
protein G were reduced and alkylated, followed by tryptic
digestion. The peptide mixture (1 ml) was subjected to nano-
liquid chromatography/electrospray ionization/tandem mass
spectrometry. More details of the analytical method can be
found in our earlier report.5
As shown in table 1, CIC-associated TSP-1 was found only
in patients with early RA and was not found in disease con-
trols (patients with SS or SLE) or healthy donors (100% spe-
cific). Twenty-two (55%) of the total of 40 patients with early
RA (56% (14/25) of the seropositive patients and 53% (8/15) of
the seronegative patients) had CIC-associated TSP-1.
PF4-containing CICs were found in only three patients (8%)
with early RA compared with 52% of the patients with
established RA.5 These PF4-containing CICs may therefore
promote disease progression.
In conclusion, we have shown that CIC-associated TSP-1 has
high potential as a novel biomarker for diagnosing early and/or
seronegative RA. Further analyses using a large number of
patients are warranted to determine the clinical benefit of
using this novel biomarker.
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Table 1 Number of patients with early RA carrying CIC-associated
TSP-1 or CIC-associated PF4














TSP-1 14 8 0 0 0
PF4 3 0 0 0 0
CIC, circulating immune complex; PF, platelet factor; RA, rheumatoid arthritis; SS,
Sjögren’s syndrome; SLE, systemic lupus erythematosus; TSP, thrombospondin.
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